We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics Rides High on Plasma, Blood Center Remains Weak
Read MoreHide Full Article
On Apr 10, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been gaining on continued momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #3 (Hold).
This leading provider of hematology products and solutions has outperformed the industry over the last three months. The stock has rallied 14.2% versus the industry’s 2.7% decline.
Haemonetics exited third-quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. Continued momentum in new business formation and expanding geographies has also helped the company deliver strong results in the quarter. Moreover, the gross and operating margin growth buoys optimism among investors about the stock.
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. For solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Further, the raised fiscal 2018 adjusted earnings guidance is encouraging. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems, which includes the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect any quick recovery in Blood Center’s outcome, which further adds to our concerns.
athenahealth has an expected long-term growth rate of 17.7% and the current-year metric is pegged at 52.8%.
Bio-Rad has an expected long-term growth rate of 20% and the current year’s stands at 42.9%.
Centene has an expected long-term growth rate of 14.4% and the same for 2018 is projected at 43.1%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Haemonetics Rides High on Plasma, Blood Center Remains Weak
On Apr 10, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been gaining on continued momentum in new business generation and geographical expansion. The stock carries a Zacks Rank #3 (Hold).
This leading provider of hematology products and solutions has outperformed the industry over the last three months. The stock has rallied 14.2% versus the industry’s 2.7% decline.
Haemonetics exited third-quarter fiscal 2018 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. Continued momentum in new business formation and expanding geographies has also helped the company deliver strong results in the quarter. Moreover, the gross and operating margin growth buoys optimism among investors about the stock.
Additionally, we are upbeat about Haemonetics’ flourish in the Plasma franchise. For solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth. Haemonetics is also confident about maintaining progress in the commercial Plasma collection business.
Haemonetics Corporation Price
Haemonetics Corporation Price | Haemonetics Corporation Quote
Further, the raised fiscal 2018 adjusted earnings guidance is encouraging. In addition, the company’s strong cash position boosts investors’ confidence.
On the flip side, Haemonetics operates in a fiercely competitive environment with respect to manual and automated systems, which includes the likes of MAK Systems.
Moreover, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Also, management doesn’t expect any quick recovery in Blood Center’s outcome, which further adds to our concerns.
Key Picks
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. , Bio-Rad Laboratories, Inc. (BIO - Free Report) and Centene Corporation (CNC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has an expected long-term growth rate of 17.7% and the current-year metric is pegged at 52.8%.
Bio-Rad has an expected long-term growth rate of 20% and the current year’s stands at 42.9%.
Centene has an expected long-term growth rate of 14.4% and the same for 2018 is projected at 43.1%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>